Outcomes of Patients With Interstitial Lung Disease and Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy
Clinical Lung Cancer · 2025
DOI: 10.1016/j.cllc.2025.07.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Samantha Q Vuong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; University of Wisconsin School of Medicine a…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Radiosurgery, Lung Neoplasms, Lung Diseases, Interstitial. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Herman and Gwendolyn Shapiro Foundation, University of Wisconsin Carbone Cancer Center.
Abstract (Originalsprache)
PURPOSE: To characterize pulmonary events after stereotactic body radiotherapy (SBRT) in patients with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD). MATERIALS AND METHODS: Patients with Stage I-II NSCLC receiving SBRT from 2004 to 2024 were reviewed. Radiation pneumonitis (RP) and lung infection were scored. Clinical and dosimetric predictors for grade ≥2 RP and pulmonary-related hospitalizations within one year were assessed using univariate analysis and multivariable analysis (MVA), adjusted for the competing risk of death. Overall survival (OS) was evaluated using the log rank test. RESULTS: Of the 500 patients included, 31 (6.2%) had ILD. Grade ≥2 RP was observed in 5 (16.1%) patients with ILD and 17 (3.6%) patients without ILD (P = .001). Grade ≥3 RP was observed in 2 (6.5%) patients with ILD and 4 (0.9%) patients without ILD (P = .048). No patient had grade 4 or higher RP. On MVA, ILD (HR: 4.44, 95% CI: 1.50-11.32, P = .009) and higher mean lung dose (HR: 1.34, 95% CI: 1.05-1.62, P = .02) predicted for RP. ILD also predicted for pulmonary-related hospitalizations (P < .05) and worse OS (P = .002). The median OS was 36.1 months (range 3.7-76.1 months) in patients with ILD and 54.3 months (range 0.8-150.3 months) in patients without ILD (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; University of Wisconsin School of Medicine and Public Health, Madison, WI.
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; University of Wisconsin Carbone Cancer Center, Madison, WI.
- Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI; University of Wisconsin Carbone Cancer Center, Madison, WI. Electronic address: baschnagel@humonc.wisc.edu.
Förderung
- NCI NIH HHS
- Herman and Gwendolyn Shapiro Foundation
- University of Wisconsin Carbone Cancer Center
Zitieren
APA
Vuong, S. Q., Liu, M., Tsarovsky, N. W., Wudtke, J. D., Wallat, E. M., Bayliss, R. A., Bassetti, M. F., & Baschnagel, A. M. (2025). Outcomes of Patients With Interstitial Lung Disease and Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2025.07.017
Vancouver
Vuong SQ, Liu M, Tsarovsky NW, Wudtke JD, Wallat EM, Bayliss RA, et al. Outcomes of Patients With Interstitial Lung Disease and Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2025.07.017
BibTeX
@article{Vuong2025,
author = {Vuong, Samantha Q and Liu, Manlu and Tsarovsky, Noah W and Wudtke, Jacob D and Wallat, Eric M and Bayliss, R Adam and Bassetti, Michael F and Baschnagel, Andrew M},
title = {Outcomes of Patients With Interstitial Lung Disease and Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy},
journal = {Clinical Lung Cancer},
year = {2025},
doi = {10.1016/j.cllc.2025.07.017}
}
EUVIMED